---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-23-008942"
form_type: "8-K"
ticker: null
cik: "0001617765"
company_name: "EVOME MEDICAL TECHNOLOGIES INC."
filed_at: "2023-04-07T23:59:59+00:00"
generated_at: "2026-06-17T04:36:44.412198+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Salona Global closes Biodex acquisition for $8M; reports 167% revenue growth to $33.6M

## Summary
- Acquired Biodex for $1M cash + $7M in installments; adds projected $26M annual revenue at ~30% gross margin.
- Transition period revenue $33.6M (167% YoY growth); gross margin $10.6M (31.4% of revenue).
- Adjusted EBITDA $435,948 (17% YoY growth); preliminary Feb 2023 revenue ~$6.7M, EBITDA ~$200K.
- Combined annualized revenue estimated at ~$65M with ~34% gross margin; order backlog ~$20M.
- Appointed Joe Martinez as SVP, Legal & Compliance, General Counsel effective March 31, 2023.

## SEC filing metadata
- accession: 0001062993-23-008942
- form_type: 8-K
- cik: 0001617765
- company_name: EVOME MEDICAL TECHNOLOGIES INC.
- filed_at: 2023-04-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/0001062993-23-008942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-23-008942
- JSON: https://secwatch.observer/filing/0001062993-23-008942.json
- Plain text: https://secwatch.observer/filing/0001062993-23-008942.txt

## Key facts
- Earnings Releases
  EVOME MEDICAL TECHNOLOGIES INC. reported next 12 months results: revenue $65 million. Guidance initiated.
  - Period: next 12 months
  - Revenue: $65 million
  - Guidance: initiated
  - Result: guidance update
  source text: With the addition of our new Biodex Physical Medicine business, the Company estimates that it will generate Annualized Revenue (defined below) of approximately $65 million, with a gross margins of approximately 34%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/0001062993-23-008942-index.htm
- Earnings Releases
  EVOME MEDICAL TECHNOLOGIES INC. reported ten months ended December 31, 2022 results: revenue $33.6 million.
  - Period: ten months ended December 31, 2022
  - Revenue: $33.6 million
  - Result: reported results
  source text: The Company also posted its audited year-end financial statements for the ten month transition period ended December 31, 2022, with a total of $33.6 million in revenue with 31.4% gross margins for the period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/0001062993-23-008942-index.htm
- Earnings Releases
  EVOME MEDICAL TECHNOLOGIES INC. reported two months ended February 28, 2023 results: revenue $6.7 million.
  - Period: two months ended February 28, 2023
  - Revenue: $6.7 million
  - Result: preliminary results
  source text: Through February 2023, the Company estimates on a preliminary basis that it is has generated revenues of approximately $6.7 million with gross profit exceeding 35% and EBITDA of approximately $200,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/0001062993-23-008942-index.htm
- M&A Transactions
  EVOME MEDICAL TECHNOLOGIES INC. completed an acquisition involving Mirion Technologies (US), Inc. for $1,000,000 in cash paid at the closing, and three installment payments to the Seller totaling $7 million (closed 2023-04-03).
  - Action: acquisition
  - Counterparty: Mirion Technologies (US), Inc.
  - Consideration: $1,000,000 in cash paid at the closing, and three installment payments to the Seller totaling $7 million
  - Closing: 2023-04-03
  source text: corporation ( "Biodex" ), which consists principally of the Biodex Physical Medicine (Rehabilitation) business (the "Acquisition" ). The consideration for the Acquisition was $1,000,000 in cash paid at the closing, and three installment payments to the Seller totaling $7 million, plus or minus a post-closing adjustment, as follows: $2 million on July 1, 2023, $3
  evidence_url: https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/0001062993-23-008942-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.